News
21 September 2022
VIVEbiotech, one of the three only companies to obtain a PERTE
VIVEbiotech has obtained the PERTE called “Salud de Vanguardia/State-Of-The-Art Health” by the Ministry of Industry of the Spanish Government which is financed with European...
Read more21 June 2022
VIVEbiotech continues the expansion of its lentiviral vector manufacturing capabilities to address the viral vector bottleneck
VIVEbiotech, a gene transfer technologies Contract Development and Manufacturing Organization (CDMO) developing and GMP manufacturing lentiviral vectors, today announces its Good Manufacturing Practice (GMP)-accredited...
Read more4 May 2022
Interview with Natalia Elizalde in The Medicine Maker
The Business Development Director of VIVEbiotech Dr. Natalia Elizalde was interviewed by The Medicine Maker on the challenges of lentiviral vector manufacture/use.
Read more2 May 2022
Gurutz Linazaroso, the CEO of VIVEbiotech, in the Medicine Maker Power List 2022
The CEO of VIVEbiotech, Dr. Gurutz Linazasoro, is part of the prestigious The Medicine Maker Power List
Read more7 April 2022
The Analytical Scientist interviews Rakel Lopez de Maturana
The Analytical Scientist interviewed Rakel Lopez de Maturana, VIVEbiotech´s Qualified Person & Regulatory Affairs Director.
Read more9 March 2022
PharmaBoardroom interviews Gurutz Linazasoro, CEO of VIVEbiotech
PharmaBoardroom, the global platform for healthcare & life sciences executives, interviewed Gurutz Linazasoro, CEO of VIVEbiotech.
Read more18 February 2022
VIVEbiotech receives the “LH Duala Euskaraz” award
VIVEbiotech has been awarded with the “LH Duala Euskaraz” prize for promoting the use of Euskara, the language of the Basque Country, on a regular...
Read more2 February 2022
PharmaBoardoom points out VIVEbiotech as one of the ten Spanish Biotechs to watch in 2022
PharmaBoardroom, a leading British media specialized in the health sector, has published an article in which it highlights VIVEbiotech as one of the ten Spanish...
Read more5 January 2022
Article on improving viral vector production in GEN
GEN recently interviewed our Business Development Director, Dr. Natalia Elizalde, with whom they spoke about improving the production of lentiviral vectors, vectors that VIVEbiotech develops...
Read moreDestacadas
4 March 2024
Spanish researchers to design proteins using AI to make advanced therapies more efficient
20 February 2024
Scrip Citeline Commercial reports VIVEbiotech’s predictions for 2024
14 February 2024
VIVEbiotech forecasts significant growth in lentiviral vectors and CAR-T therapies for 2024
13 February 2024
9 February 2024